RxDoctor Payments DataLook up a doctor →

Eric Secemsky, MD

Interventional Cardiology · Boston, MANPI 1942535489

Payments from drug & device makers

$7,303,902in general payments, 2019–2025

Across 1,157 payments — averaging $6312.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$3.7M
  • Boston Scientific$1.7M
  • Bard Peripheral Vascular, Inc.$462K
  • Medtronic$458K
  • Cook Research Incorporated$194K
  • Abbott$134K
  • plus $721K from 45 others
$474,765in research payments, 2019–2025

Across 20 payments — averaging $23,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$457K
  • Surmodics, Inc.$10K
  • Medtronic$7K
  • Veryan Medical Incorporated$1K

What the payments were for

  • Consulting fees$665,51058%
  • Speaking & faculty fees$216,58119%
  • Grants$2,2000%
  • Travel & lodging$107,1679%
  • Food & beverage$29,1683%
  • Gifts$1080%
  • Other$133,51012%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,303,902 in reported general payments places this provider in the 95th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$69,237
Medicare patients
311
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban20$23,908
EliquisApixaban17$15,829
Cilostazol20$957
Atorvastatin Calcium20$348
Rosuvastatin Calcium22$333
Metoprolol Succinate11$176
Carvedilol21$157
Losartan Potassium20$141
Amlodipine Besylate18$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$7,717$23,90820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 128 interventional cardiology providers in Massachusetts.

Other interventional cardiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →